All In Biotech

Drug Trial Radar · NCT01159080

Treatment of the optImuM Dose of calcineUrin Inhibitor and Mycophenolate Sodium in Kidney Recipients

Organ Function Preservation by the Combination Treatment of the optImuM Dose of calcineUrin Inhibitor and Mycophenolate Sodium in Kidney Recipients: OPTIMUM Study

Last checked: Nov 20, 2026Latest source record: Mar 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

350

Actual

Start

Apr 1, 2010

Primary completion

Oct 30, 2016

Study completion Nov 30, 2016

Sponsor

Lead sponsor
Asan Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Seoul National University Hospital; Samsung Medical Center
First posted
Jul 9, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To clarify that tacrolimus-sparing regimen with minimal tacrolimus dose together with mycophenolate sodium dose increment will preserve renal allograft function without rising adverse effects Primary endpoints: 1. estimated GFR (MDRD equation) 12 months after randomization 2. estimated GFR change from randomization to end of the study (calculated by MDRD equation and Nankivell equation)

Conditions

  • Kidney Transplantation

Interventions

  • routine dose tacrolimus and less myforticDrug

    oral regular dose of tacrolimus + less dose of myfortic trough level of tacrolimus will be 5-10 ng/mL and oral myfortic dose will be 180-360 mg twice a day

  • reduced dose tacrolimus and conventional myforticDrug

    low dose of tacrolimus + maximum dose of myfortic target trough level of tacrolimus should be reduced to 2-5 ng/mL for 3 months after randomization and oral MPS dose increased to 540-720mg twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. estimated GFR (MDRD equation)12 months after randomizationTime frame: 12 months after randomization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center

    Seoul, Asan Medical Center, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.